Stocktoria
Cartesian Therapeutics, Inc. RNAC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-06-22
Cartesian Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $38.9M | $26.0M | $110.8M | $85.1M | $16.6M | $6.7M | $903,000 | $207,000 | $8.1M |
| R&D expense | $58.0M | $45.1M | $71.3M | $72.4M | $68.7M | $54.5M | $42.7M | $47.7M | $45.2M | $29.7M |
| Operating income | -$143.4M | -$43.9M | -$86.4M | $14.5M | -$4.6M | -$56.8M | -$52.5M | -$65.0M | -$63.8M | -$34.7M |
| Interest expense | — | — | $2.8M | $3.0M | $2.8M | $1.6M | $1.5M | $1.5M | $1.2M | $1.3M |
| Income tax | -$9.2M | $287,000 | -$19.0M | -$609,000 | $16.0M | $0 | $0 | — | — | — |
| Net income | -$130.3M | -$77.4M | -$219.7M | $35.4M | -$25.7M | -$68.9M | -$55.4M | -$65.3M | -$65.3M | -$36.2M |
| EPS (diluted) | $-5.02 | $-4.49 | $-49.76 | $0.10 | $-0.22 | $-0.68 | $-1.22 | — | — | — |
| Operating cash flow | -$73.9M | -$23.7M | -$51.2M | -$31.6M | -$60.4M | $34.9M | -$51.4M | -$59.2M | -$52.0M | -$19.8M |
| Free cash flow | -$79.4M | -$32.8M | -$51.4M | -$32.8M | -$61.5M | $34.1M | -$51.5M | -$60.0M | -$52.8M | -$20.3M |
| Cash & equivalents | $125.1M | $212.6M | $76.9M | $106.4M | $114.1M | $138.7M | $89.9M | $37.4M | $70.6M | $58.7M |
| Total assets | $296.4M | $435.0M | $305.1M | $165.9M | $159.9M | $165.4M | $99.6M | $44.5M | $101.1M | $89.3M |
| Total liabilities | $422.7M | $441.8M | $444.7M | $72.1M | $137.4M | $183.4M | $91.2M | $49.9M | $49.3M | $34.3M |
| Shareholders' equity | -$126.2M | -$6.8M | -$440.2M | $93.8M | $22.5M | -$18.0M | $8.4M | -$5.4M | $51.8M | $55.0M |
Growth · year-over-year · Revenue CAGR -11.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -92.8% | +49.6% | -76.5% | +30.2% | +412.6% | +148.6% | +639.4% | +336.2% | -97.4% | +34.5% |
| Net income growth | — | — | -721.0% | — | — | — | — | — | — | — |
| EPS growth | — | — | -49860.0% | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | -280.4% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.